General Information of Drug Combination (ID: DCJLPYK)

Drug Combination Name
NVP-AUY922 Lenvatinib
Indication
Disease Entry Status REF
Ewing sarcoma Investigative [1]
Component Drugs NVP-AUY922   DMTYXQF Lenvatinib   DMB1IU4
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: TC-71
Zero Interaction Potency (ZIP) Score: 42.417
Bliss Independence Score: 40.209
Loewe Additivity Score: 3.853
LHighest Single Agent (HSA) Score: 10.313

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of NVP-AUY922
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
NVP-AUY922 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Heat shock protein 90 alpha (HSP90A) TT78R5H HS90A_HUMAN Inhibitor [10]
------------------------------------------------------------------------------------
NVP-AUY922 Interacts with 23 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Anterior gradient protein 2 homolog (AGR2) OTRRZT7W AGR2_HUMAN Increases Expression [9]
Fibroblast growth factor 1 (FGF1) OT8I64X8 FGF1_HUMAN Decreases Expression [9]
ATP synthase subunit beta, mitochondrial (ATP5F1B) OTLFZUQK ATPB_HUMAN Decreases Expression [9]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Decreases Expression [11]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [11]
Mast/stem cell growth factor receptor Kit (KIT) OTHUY3VZ KIT_HUMAN Decreases Expression [11]
S-formylglutathione hydrolase (ESD) OTUSIBPS ESTD_HUMAN Increases Expression [9]
Elongation factor 2 (EEF2) OTZ7SZ39 EF2_HUMAN Increases Expression [9]
Intron Large complex component GCFC2 (GCFC2) OTC7FRXL GCFC2_HUMAN Increases Expression [9]
Proteasome subunit alpha type-1 (PSMA1) OTNBVM2U PSA1_HUMAN Increases Expression [9]
M-phase inducer phosphatase 3 (CDC25C) OTPQI71S MPIP3_HUMAN Decreases Expression [11]
Radixin (RDX) OTNSYUN6 RADI_HUMAN Increases Expression [9]
Serpin H1 (SERPINH1) OTKGI7BS SERPH_HUMAN Decreases Expression [9]
Small ubiquitin-related modifier 3 (SUMO3) OTTUJQJ1 SUMO3_HUMAN Decreases Expression [9]
Peptidyl-prolyl cis-trans isomerase A (PPIA) OTHJMWQQ PPIA_HUMAN Increases Expression [9]
Echinoderm microtubule-associated protein-like 5 (EML5) OT0EFCPB EMAL5_HUMAN Increases Expression [9]
Interleukin enhancer-binding factor 3 (ILF3) OTKMZ5K5 ILF3_HUMAN Decreases Expression [9]
Eukaryotic translation initiation factor 3 subunit I (EIF3I) OTE07WND EIF3I_HUMAN Decreases Expression [9]
Phenylalanine--tRNA ligase beta subunit (FARSB) OT8N9TT5 SYFB_HUMAN Increases Expression [9]
Protein PALS2 (PALS2) OTV12NKE PALS2_HUMAN Increases Expression [9]
Cingulin (CGN) OTBCQ8AQ CING_HUMAN Decreases Expression [9]
Poly polymerase 2 (PARP2) OTYL81ZI PARP2_HUMAN Increases Expression [9]
Hypoxia up-regulated protein 1 (HYOU1) OTBGBSOV HYOU1_HUMAN Decreases Expression [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 23 DOT(s)
Indication(s) of Lenvatinib
Disease Entry ICD 11 Status REF
Thyroid cancer 2D10 Approved [4]
Thyroid gland follicular carcinoma N.A. Approved [5]
Thyroid gland papillary carcinoma N.A. Approved [5]
Hepatocellular carcinoma 2C12.02 Phase 3 [6]
Renal cell carcinoma 2C90 Phase 3 [7]
Melanoma 2C30 Phase 2 [6]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [7]
Ovarian cancer 2C73 Phase 1 [8]
Non-small-cell lung cancer 2C25.Y Application submitted [7]
Lenvatinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------
Lenvatinib Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 ClinicalTrials.gov (NCT01854034) Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR. U.S. National Institutes of Health.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027019)
4 FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 208627.
5 Lenvatinib FDA Label
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
9 Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry. Cells. 2019 Jul 31;8(8):806. doi: 10.3390/cells8080806.
10 Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
11 Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma. Cancer. 2013 Jan 15;119(2):293-303. doi: 10.1002/cncr.27743. Epub 2012 Jul 18.
12 Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci Rep. 2019 Apr 1;9(1):5404.